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IMPORTANCE Previous studies have indicated a heritable component of the etiology of
neurodegenerative diseases such as Alzheimer disease (AD), frontotemporal dementia (FTD),
and progressive supranuclear palsy (PSP). However, few have examined the contribution of
low-frequency coding variants on a genome-wide level.
OBJECTIVE To identify low-frequency coding variants that affect susceptibility to AD, FTD,
and PSP.
DESIGN, SETTING, AND PARTICIPANTS Weused the Illumina HumanExome BeadChip array to
genotype a large number of variants (most of which are low-frequency coding variants) in a
cohort of patients with neurodegenerative disease (224 with AD, 168 with FTD, and 48with
PSP) and in 224 control individuals without dementia enrolled between 2005-2012 from
multiple centers participating in the Genetic Investigation in Frontotemporal Dementia and
Alzheimer’s Disease (GIFT) Study. An additional multiancestral replication cohort of 240
patients with AD and 240 controls without dementia was used to validate suggestive
findings. Variant-level association testing and gene-based testing were performed.
MAIN OUTCOMES ANDMEASURES Statistical association of genetic variants with clinical
diagnosis of AD, FTD, and PSP.
RESULTS Genetic variants typed by the exome array explained 44%, 53%, and 57% of the
total phenotypic variance of AD, FTD, and PSP, respectively. An association with the known
AD gene ABCA7was replicated in several ancestries (discovery P = .0049, European P = .041,
African American P = .043, and Asian P = .027), suggesting that exonic variants within this
genemodify AD susceptibility. In addition, 2 suggestive candidate genes, DYSF
(P = 5.53 × 10−5) and PAXIP1 (P = 2.26 × 10−4), were highlighted in patients with AD and
differentially expressed in AD brain. Corroborating evidence from other exome array studies
and gene expression data points toward potential involvement of these genes in the
pathogenesis of AD.
CONCLUSIONS AND RELEVANCE Low-frequency coding variants with intermediate effect size
may account for a significant fraction of the genetic susceptibility to AD and FTD.
Furthermore, we found evidence that coding variants in the known susceptibility gene
ABCA7, as well as candidate genes DYSF and PAXIP1, confer risk for AD.
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G enetics studieshave revealedagenetic contribution tosusceptibility for common or sporadic forms of neu-rodegenerativediseasesuchasAlzheimerdisease (AD),
frontotemporal dementia (FTD), and progressive supra-
nuclear palsy (PSP, a syndrome characterized by oculomotor
and gait abnormalities). In AD, early genetic mapping ap-
proaches have identified rare variants in genes such as APP,
PSEN1, andPSEN2 thatcause familial, early-onset forms.1APOE
wasalsopinpointedasa late-onsetADsusceptibilitygene.2Ge-
nome-wideassociationstudies3-5 (GWAS) targetedtowardcom-
mon variants in primarily European populations have identi-
fiedmanyvariants associatedwithAD,most clearlynearAPOE
but also consistently near ABCA7, BIN1, CLU, CR1, PICALM,
SORL1, and other genes. Next-generation sequencing ap-
proacheshavealso found rarevariantswith strongeffect in the
MAPT and TREM2 genes.6,7
In FTD, themost frequently observedmutations in famil-
ial cases occur in C9ORF72, GRN,MAPT, TARDBP, and other
genes.8 In sporadic cases, a haplotype variant on the long arm
of chromosome17hasbeen repeatedly associatedwithPSP.9-11
In addition, GWAS have been performed for sporadic cases of
FTD, identifying associated single-nucleotide polymor-
phisms (SNPs) nearTMEM106B12 andBTNL2/HLA-DRA/HLA-
DRB5 and RAB38/CTSC,13 as well as for PSP, identifying asso-
ciated SNPs nearMAPT, EIF2AK3, STX6, andMOBP.11
Despite progress in understanding the genetics of neuro-
degenerative diseases, known genetic risk factors cannot
explain a large portion of the heritability of these diseases. For
example, in AD, all common variants (including known and
unknown risk variants) have been predicted to account for
less than 25% of disease variance,14 and known high-pene-
trance rare variants account for few cases, collectively totaling
only a fraction of the estimated 58% to 79% heritability of
AD.15 Some of this missing heritability may be due to a blind
spot in conventional genetic studies to date. A moderately
rare variant with moderate effect size would be too uncom-
mon to be tagged by a standard genotyping array and have too
small of an effect to be detected by linkage or genome
sequencing in practical sample sizes. The exome array bridges
this gap by genotyping at low cost more than 200 000 coding
variants identified through sequencing studies (Figure 1). This
approach has been applied to phenotypes such as insulin
homeostasis,16 bronchopulmonary dysplasia,17 and heart
disease.18,19 For AD, Chung et al20 recently reported an exome
array study in Korean participants that found an association
with APOE, APOC1, and TOMM40 variants (near the APOE
locus) but did not identify novel genetic variants. Herein, we
report findings from the application of the exome array to the
multiancestral Genetic Investigation in Frontotemporal
Dementia and Alzheimer’s Disease (GIFT) Study cohort to
determine the contribution of low-frequency coding variants
to susceptibility to sporadic AD, PSP, and FTD.
Methods
Study Cohort
Patients and healthy control individuals were enrolled be-
tween 2005-2012 at theMemory andAging Center, University
of California, San Francisco, as part of the GIFT Study, an in-
vestigation of the genetics of neurodegenerative disease .21,22
Written consent was obtained at the participating institu-
tions. The study was approved by the Institutional Review
Board of the University of California, Los Angeles. An addi-
tional 32 DNA samples frompatientswith PSPwere extracted
from postmortem brain tissue from the New York Brain Bank
atColumbiaUniversity (NewYork,NewYork).Asubsetof these
individualswere initially selected for genotypingusing the Il-
lumina HumanExome BeadChip array (Table 1). Patients di-
agnosed as having FTD with motor neuron disease (FTD/
MND)were excluded from further analysis owing to the small
sample size and potential genetic heterogeneity.
Replication Cohort
As part of the GIFT Study, individuals were also enrolled from
other sites, including Emory University, University of South-
ern California, and University of California at Berkeley, Davis,
Irvine, and Los Angeles. Following initial data analysis, 480
individuals from this additional group of patients, including
240 patients with AD and 240 controls without dementia,
were genotyped (Table 2). These individuals were analyzed as
above but owing to genetic heterogeneity were divided into 4
general groups (European, African American, Latino, and
Asian) based on self-reported ancestry. To ensure proper clas-
sification and minimize the inclusion of misplated samples,
genetic ancestry was also estimated by multidimensional
Figure 1. Comparison of the ExomeArray and Related Genotyping and Sequencing Technologies
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The exome array serves as a bridge
between conventional
single-nucleotide polymorphism
(SNP) genotyping array and exome
sequencing. The exome array assays
primarily variants within exonic
regions of the DNA, similar to exome
sequencing; however, the location of
the variants must be known a priori.
The cost of the exome array is
typically similar to that of other
genotyping arrays and is much less
expensive than that of exome
sequencing.
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Table 1. Demographic Information for the Discovery Cohort
Characteristic
AD
(n = 224)
Control
(n = 224)
FTD
(n = 168)
FTD/MND
(n = 8)
PSP
(n = 48)
Age, median (range), y 71 (42 to ≥89) 71 (35 to ≥89) 67 (35 to ≥89) 63 (35 to 80) 76 (55 to ≥89)
Sex, No. (%)
Male 12 (56.7) 94 (42.0) 95 (56.5) 8 (100) 19 (39.6)
Female 97 (43.3) 130 (58.0) 73 (43.5) 0 29 (60.4)
Ancestry, No. (%)
European 195 (87.1) 183 (81.7) 144 (85.7) 8 (100) 12 (25.0)
African American 2 (0.9) 0 0 0 0
Latino 0 4 (1.8) 1 (0.6) 0 0
Asian 20 (8.9) 27 (12.1) 9 (5.4) 0 1 (2.1)
Other 3 (1.3) 4 (1.8) 7 (4.2) 0 2 (4.2)
Unknown 4 (1.8) 6 (2.7) 7 (4.2) 0 33 (68.8)
APOE genotype, No. (%)
E2/E2 1 (0.4) 1 (0.4) 0 0 1 (2.1)
E2/E3 7 (3.1) 19 (8.5) 16 (9.5) 1 (12.5) 3 (6.3)
E2/E4 4 (1.8) 1 (0.4) 1 (0.6) 0 2 (4.2)
E3/E3 99 (44.2) 157 (70.1) 107 (63.7) 5 (62.5) 36 (75.0)
E3/E4 92 (41.1) 40 (17.9) 40 (23.8) 1 (12.5) 6 (12.5)
E4/E4 21 (9.4) 6 (2.7) 4 (2.4) 1 (12.5) 0
Chromosome 17q21.31
haplotype, No. (%)
H1/H1 91 (40.6) 132 (58.9) 107 (63.7) 4 (50.0) 43 (89.6)
H1/H2 48 (21.4) 52 (23.2) 33 (19.6) 3 (37.5) 5 (10.4)
H2/H2 4 (1.8) 10 (4.5) 7 (4.2) 0 0
Untyped 81 (36.2) 30 (13.4) 21 (12.5) 1 (12.5) 0
Abbreviations: AD, Alzheimer
disease; FTD, frontotemporal
dementia; FTD/MND, FTDwith
motor neuron disease; PSP,
progressive supranuclear palsy.
Table 2. Demographic Information for the Replication Cohort
Characteristic
No. (%)
European
(n = 135)
African American
(n = 271)
Latino
(n = 50)
Asian
(n = 24)
Diagnosis
AD 68 (50.4) 138 (50.9) 21 (42.0) 13 (54.2)
Control 67 (49.6) 133 (49.1) 29 (58.0) 11 (45.8)
Sex
Male 68 (50.4) 73 (26.9) 19 (38.0) 8 (33.3)
Female 57 (42.2) 198 (73.1) 31 (62.0) 16 (66.7)
Unknown 10 (7.4) 0 0 0
Contributing center
Emory University 21 (15.6) 223 (82.3) 0 0
University of California, Berkeley 33 (24.4) 14 (5.2) 8 (16.0) 8 (33.3)
University of California, Davis 3 (2.2) 32 (11.8) 23 (46.0) 5 (20.8)
University of California, Irvine 55 (40.7) 2 (0.7) 5 (10.0) 1 (4.2)
University of California, Los Angeles 2 (1.5) 0 0 0
University of California, San Francisco 20 (14.8) 0 0 6 (25.0)
University of Southern California 1 (0.7) 0 14 (28.0) 4 (16.7)
APOE genotype
E2/E2 1 (0.7) 2 (0.7) 0 0
E2/E3 4 (3.0) 16 (5.9) 2 (4.0) 1 (4.2)
E2/E4 5 (3.7) 9 (3.3) 3 (6.0) 0
E3/E3 41 (30.4) 87 (32.1) 34 (68.0) 8 (33.3)
E3/E4 21 (15.6) 86 (31.7) 9 (18.0) 3 (12.5)
E4/E4 9 (6.7) 12 (4.4) 1 (2.0) 2 (8.3)
Untyped 54 (40.0) 59 (21.8) 1 (2.0) 10 (41.7) Abbreviation: AD, Alzheimer
disease.
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scaling using the PLINK whole-genome association analysis
tool set (http://pngu.mgh.harvard.edu/purcell/plink/) using
the entire set of genotyped variants by the exome array. Fol-
lowing this procedure, 44 samples were suspected of misclas-
sification and were removed from further analysis.
ExomeArray Genotyping
Exonic and nonexonic variants were genotyped using the Il-
lumina Infinium HumanExome BeadChip kit. While mostly
consisting of coding variants from prior sequencing studies,
the exome arrays also included markers for previously de-
scribed GWAS hits, ancestry-informative markers, randomly
selected synonymousvariants,HLA tag SNPs, andothers,16 in
total comprising250 272genotypedmarkersper sample.Qual-
ity control procedures were enacted to remove suspect vari-
ants and minimize the effect of population structure on the
data analysis. The eMethods, eFigure 1, and eFigure 2 in the
Supplement provide further details on genotyping and data
preprocessing procedures.
Statistical Analysis
The total phenotypic (disease) varianceexplainedby thegeno-
typedvariantswasdeterminedusingarestrictedmaximumlike-
lihood model implemented in Genome-Wide Complex Trait
Analysis (GCTA; http://www.complextraitgenomics.com
/software/gcta/).Variant-levelassociationwithAD,FTD,andPSP
was tested using a logistic regressionmodel that corrected for
populationstructure.Theassociationonthegenelevelwastested
using the sequence kernel association test (SKAT),23 a nonbur-
den test that is sensitive in thepresenceofneutral genetic vari-
ants. Genes that showed suggestive associationswithADwere
alsotestedinpreviouslydescribedbrainmessengerRNA(mRNA)
expressiondatasets.24,25TheeMethods in theSupplementpro-
videsamoredetaileddescriptionofthestatisticalmethodsused.
Summary statistics and individual-level data are available
fromtheNIAGenetics ofAlzheimer’sDiseaseDataStorageSite
(NIAGADS; https://www.niagads.org/, accession number
NG00040).
Results
Patient Characteristics
The initialdiscoverysample included224patientswithAD, 168
patientswithFTD,8patientswithFTD/MND,48patientswith
PSP, and224healthycontrols.Demographic characteristics are
summarized in Table 1. The ancestral makeup of this sample
waspredominantlyEuropean (80.7%overall). Consistentwith
their known roles in the respective diseases, individuals clas-
sified as having AD showed high prevalence of the APOE ε4
allele (41.1% ε3/ε4 and 9.4% ε4/ε4), and individuals classi-
fied as having PSP showed high prevalence of the H1 haplo-
type (89.6% H1/H1 and 10.4% H1/H2). The replication cohort
consisted of amore ancestrally heterogeneous set of patients
and controls (Table 2).
Low-Frequency Exonic Variants Explain a Fraction
of the Phenotypic Variation in AD and FTD
Foreachof the3diseases (AD,FTD,andPSP), theGCTAsoftware
wasappliedtothedataset toestimate thevarianceexplainedby
the following3different classesofvariants: all variants, includ-
ingnonexonicvariants;exonicvariantsonly;andlow-frequency
exonicvariants,withminor allele frequency<5%. Ineachcase,
asubstantialportionof theobservedphenotypicvariancecould
beexplainedbyall the typedvariants (Table3).However,owing
to the small sample sizes on which each of these estimates is
based, the standard error of eachmeasurement is high.
Variant-Level Association Testing Identifies Significant
AssociationsWith Known andNovel Loci
A logistic regression procedurewas performed on our discov-
ery cohort to test for an associationwith AD, FTD, or PSP. Our
method largely controlled for genomic inflation due to popu-
lation stratification in each of the 3 disease categories (eFig-
ure 3 in the Supplement). Two variants were suggestively as-
sociatedwithAD, rs769449 (P = 1.14 × 10−7;minor allele odds
ratio [OR], 3.0) andrs4420638 (P = 2.58 × 10−6;minoralleleOR,
2.3). Both variants are within the APOE/TOMM40/APOC1 re-
gion on chromosome 19 identified in previous genetic
studies.2-5 Onevariantwas associatedwithFTD, exm2250002
(P = 2.08 × 10−6;minor alleleOR,0.8), corresponding to a syn-
onymousexonicvariant in theolfactory receptor genesOR9G1
andOR9G9.Novariants reached the suggestivePvalue thresh-
old (1 × 10−5) in the PSP cohort.Manhattan plots depicting as-
sociations in AD, FTD, and PSP are shown in Figure 2.
ExomeArray Genotyping Replicates Some Previous
Associations Found in AD and PSP
Thirty-nine polymorphisms previously associated with AD
and 9 polymorphisms associated with PSP (National Human
Table 3. GCTA Explained Variance Analysis
Variable
Variance Explained (SE)
AD FTD PSP
All exome array variantsa 0.44 (0.39) 0.53 (0.36) 0.57 (0.44)
Exonic fraction 0.50 (0.36) 0.45 (0.35) 0.26 (0.56)
Low-frequency exonic fractionb 0.41 (0.39) 0.42 (0.37) 0.03 (0.58)
Abbreviations: AD, Alzheimer disease; FTD, frontotemporal dementia; GCTA, Genome-Wide Complex Trait Analysis (http://www.complextraitgenomics.com
/software/gcta/); PSP, progressive supranuclear palsy.
a Includes genome-wide association studies hits, HLA tag single-nucleotide polymorphisms, custom content, ancestry-informative single-nucleotide
polymorphisms, and others.
b Less than 5%minor allele frequency between all disease cohorts and control subjects.
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Genome Research Institute Genome-Wide Association Studies
Catalog; http://www.genome.gov/gwastudies/) were typed by
the exomearray.Reported susceptibility loci for FTDwerenot
typedonthisplatform.Wetested theassociationbetweeneach
of these variants and their respective disease in our cohort, as
calculatedby the logistic proceduredescribedpreviously. For
AD, the Bonferroni correction for 39 tests at a familywise er-
ror rate of .05 yielded a P value threshold at .0013. Two asso-
ciationsnearAPOE, rs2075650 (P = 2.05 × 10−5) and rs4420638
(P = 2.58 × 10−6), surpassed this predefinedP value threshold
(eTable 1 in theSupplement).While theother testedGWASvari-
antswere not significantly associatedwith AD, the overall di-
rection of the association was highly consistent with previ-
ously reported results,3-5 and 23 of 32 SNPs for which the risk
allele was unambiguous showed the same direction of effect
as previously reported (P = .010, binomial test).
For PSP, the Bonferroni correction for 9 tests at a family-
wise error rate of .05 yielded a P value threshold at .0056. A
singlevariant exceeded this threshold, rs8070723 (P = .00043)
on chromosome 17 nearMAPT (eTable 2 in the Supplement).
Similar to the AD cohort, the direction of the association was
highly consistentwith previously reported results,11with 8of
9 SNPs showing the same direction of effect (P = .019, bino-
mial test).
Gene-Level Testing Suggests Several AD Candidate Genes
Gene-level hypothesis testing was performed using SKAT-
derivedPvalues for 17 141genes (that containedat least 1 typed
variant after quality control). Using apermutationprocedure, a
false discovery rate of 50% was expected to be controlled at a
SKAT-derivedPvalueof4.54 × 10−4 forAD,5.06 × 10−4 forFTD,
and9.65 × 10−5 for PSP. ForAD, the following 6 genes exceeded
Figure 2. Manhattan Plot of Associations in Alzheimer Disease, Frontotemporal Dementia, and Progressive Supranuclear Palsy
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this threshold:DYSF,PAXIP1,TOP1MT,C3ORF1, SETDB1, and
CRISPLD1 (P = 5.53 × 10−5, P = 2.26 × 10−4, P = 2.29 × 10−4,
P = 3.93 × 10−4, P = 4.13 × 10−4, and P = 4.54 × 10−4, respec-
tively). For FTD, the following 8 genes exceeded the thresh-
old: RAB21, AKR1B10, C9ORF6, CD5L, WDR38, OPHN1,
ADORA3, and IKBKAP (P = 4.65 × 10−5, P = 4.83 × 10−5,
P = 2.55 × 10−4,P = 3.65 × 10−4,P = 3.85 × 10−4,P = 4.78 × 10−4,
P = 4.79 × 10−4, and P = 5.06 × 10−4, respectively). For PSP, 2
genes exceeded the threshold, OR1Q1 and VWA3A
(P = 3.00 × 10−5 and P = 9.65 × 10−5, respectively).
We attempted to replicate the findings for AD in an addi-
tionalmultiancestral cohort of 240 cases and240 controls.No
further samples from patients with FTD or PSP were avail-
able, so those results could not be tested. Using the Bonfer-
roni correction, a P value threshold of .0021 (considering 6
genes times 4 ancestry categories, for a total of 24 tests) was
determined to control for a familywise error rate of .05. None
of the suggestive genes identified for ADwere significant un-
der this threshold in any ancestral category in the replication
cohort (eTable 3 in the Supplement). However, several genes
trended toward significance in some cases, includingDYSF in
Europeans (P = .076), PAXIP1 in Latinos and Asians (P = .016
and P = .037, respectively), and TOP1MT in African Ameri-
cans (P = .0059). Because of previous reports of the involve-
ment ofDYSF andPAXIP1 in theAD literature (see theDiscus-
sion section below),26,27 these genes were considered
interesting candidate genes for AD susceptibility. Overall, we
analyzed 38variants inDYSF (including 3 synonymous and 35
missense) and 5 variants in PAXIP1 (including 1 synonymous
and4missense) typedbytheexomearray,demonstratingvaria-
tion in our cohort, and passing quality control criteria.
We further identified71 genespreviously implicated inge-
netic studies of AD as categorized in the Human Gene Muta-
tion Database28 (version 2014.1) and extracted the associa-
tion statistics in the initial discovery set and the 4 replication
cohorts. Only ABCA7 (OMIM 605414) (SKAT discovery
P = .0049) reachednominal significance.Notably, the SKATP
valuewasalsonominally significant in theEuropean (P = .041),
African American (P = .043), and Asian (P = .027) replication
cohorts but not the Latino (P = .61) cohort.
DYSF and PAXIP1 Transcripts Are Differentially
Expressed in AD Brain
To further solidifywhetherDYSF (OMIM603009) andPAXIP1
(OMIM608254) are involved in thepathogenesis ofAD,weex-
amined their relativeexpression levels inpatientswithADand
controlswithoutdementia inapublishedmicroarraydataset.24
The expression of DYSF and PAXIP1 was significantly differ-
ent between cases and controls in each of the examined brain
regions (Figure 3). In the prefrontal cortex, visual cortex, and
cerebellum, the expression ofDYSFwas increased in patients
with AD (P < 2.2 × 10−16, P = 2.33 × 10−15, and P = .00080, re-
spectively). These findings were corroborated by indepen-
dent data,25which also showed increased expression ofDYSF
in the cerebral cortex of patients with AD (P = .00023). Simi-
larly, the expression ofPAXIP1 in the prefrontal cortex, visual
Figure 3. Differential Expression ofDYSF and PAXIP1 in Alzheimer Disease (AD) Brain
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Shown is the expression of DYSF (A)
and PAXIP1 (B) in a public microarray
data set of brain messenger RNA,
grouped by brain region, in patients
with AD (dark gray) vs healthy control
subjects without dementia (light
gray). The vertical axis represents the
normalized expression residual,
corrected for technical covariates.
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cortex, and cerebellum was increased in patients with AD
(P = 3.6 × 10−14, P = .0034, and P = .00095, respectively).
Discussion
We evaluated the contribution of exonic variants to neurode-
generative disease susceptibility in a multiancestral cohort
totaling 464 patients with AD, 168 patients with FTD, 48
patients with PSP, and 464 controls without dementia. We
found that low-frequency (<5%) coding variants explain a siz-
able proportion of the phenotypic variance in AD and FTD,
although the confidence limits for this estimate are large
owing to our sample size. Well-known associations with the
APOE locus for AD and 17q21.31 haplotype for PSP were repli-
cated, and a novel susceptibility locus was identified at
exm2250002 for FTD. Whether this variant is a true genetic
signal is questionable given that it was also the most signifi-
cant signal in the PSP cohort (P = 2.03 × 10−5) and corresponds
to a synonymous variant within OR9G1/OR9G9, members of
the polymorphic olfactory receptor family. Gene-level testing
identified suggestive signals from DYSF and PAXIP1 in AD,
and a trend toward significance was observed in a replication
cohort in several of the tested ancestral categories. A possible
contribution to disease risk from exonic variants in the AD
susceptibility gene ABCA7 was also detected in multiple
ancestral categories. However, we caution that these results
are merely suggestive and await validation in well-powered
cohorts andmodel systems.
The focus of the exome array on coding variation, much
ofwhich has low frequency in the general population,means
that large sample sizes are needed to observe statistically sig-
nificant effects, unless the effect sizes are large, as is the case
with the association of the APOE ε4 allele with AD. We esti-
mated that a variant at 5%minor allele frequency must have
a greater than 4-fold OR to achieve 80% power to identify in
our AD discovery cohort. Therefore, our initial cohort of 672
patients and controls and our follow-up cohort of 480 pa-
tients and controls are underpowered to detect associations
with rarevariantsofmodestor intermediateeffect sizes.Taken
togetherwithheritabilityestimates,ouranalyses indicatedthat
rare variants of low or modest effect have a role in AD, FTD,
and PSP, late-onset diseases for which deleterious alleles are
presumably under weak selective pressure.
Furthermore, while the GIFT Study cohort enabled test-
ing of an association in multiple ancestral groups simultane-
ously,our resultswere limitedbythesmall samplesizes.There-
fore, our findings do not exclude the possibility that exonic
variantswith lower frequency or effect size are present in the
general population. In fact, the strongassociationwithABCA7
(a GWAS-implicated AD susceptibility gene) by SKAT in sev-
eral ancestral populations strongly suggests that coding vari-
ants ofmodest effect sizewithin this gene are associatedwith
AD risk. Previous GWAS have reported associations with in-
tronic polymorphisms suchas rs4147929,5 rs115550680,29 and
rs3764650,4 aswell as themissensepolymorphismrs3752246.3
It is possible that these variants may tag haplotypes contain-
ing causal, exonic variants. Therefore, it is reasonable to at-
tempt to identify novel candidate genes containingmultiple,
low-frequency coding variants that may contribute to AD.
Whilenot strictly genome-wide significant, genewise test-
ing results reinforce prior findings that have implicated both
DYSF andPAXIP1 in thepathogenesis ofAD.DYSFencodes the
protein dysferlin, and mutations in this gene are known to
cause autosomal recessive muscle diseases such as Miyoshi
myopathy30 and limb-girdle muscular dystrophy type 2B,31
known as dysferlinopathies. In skeletal muscle, dysferlin is
thought to have a role in calcium-dependent sarcolemma
repair.32,33 Although its function in the central nervous sys-
tem has not been extensively elaborated, dysferlin has been
shown to accumulate in endothelial cells near multiple scle-
rosis lesions34andwithinAβplaquesofpatientswithAD.26The
colocalizationof dysferlin andAβ42 aggregateswas alsodem-
onstrated in sporadic inclusionbodymyositis, suggesting that
Aβ may sequester dysferlin and interfere with its normal re-
pair functions in skeletal muscle.35
Thesecondhighlightedgene,PAXIP1, encodes foranuclear
protein with 6 BRCT domains, hinting at its function in DNA
repairpathways.36PAXIP1mayparticipate inp53activationme-
diated by the ataxia-telangiectasia mutated (ATM) serine/
threonine kinase.36-38 Although variants in PAXIP1 have not
been definitively associatedwith disease, Rademakers et al27
identified a significant linkage peak at 7q36 in a large pedi-
gree with multiplex AD. The risk allele of the D7S798marker
also appeared to increaseAD riskby 2.7 times in aDutchpopu-
lation-based cohort.27 Sequencing of the coding exons of 29
candidate genes revealed only a single rare variant, a synony-
mous Ala626 change in PAXIP1.
Toour knowledge, theneuropathological findings byGal-
vin et al26 and the linkage study byRademakers et al27 are the
only publications to date that implicate DYSF and PAXIP1 in
the pathogenesis of AD. Our analysis of publishedmicroarray
studies indicated increases inDYSFandPAXIP1mRNAexpres-
sion in brain regions of patients with AD. However, these re-
sults donotprovidedirect evidenceof the roles of these genes
inAD. In contrast, the exomearray results add additional sup-
port for the causal pathogenicity of DYSF and PAXIP1. Al-
thoughwecouldnotascertainwhetheranyof theassayedvari-
ants directly affected the expression ofDYSF and PAXIP1, the
fact that thesegeneswereboth identifiedbyexomearrayanaly-
sis and by differential expression analysis provides conver-
gent evidence for their involvement in AD. Besides partial,
nominal replication within our cohort, our findings are fur-
ther corroboratedbya recentlypublishedexomearray study20
inAD reporting a strong (butnot genome-wide significant) as-
sociation for DYSF (P = 1.6 × 10−5) with AD in a Korean co-
hort; the associationwithPAXIP1wasnot reported. Theover-
lapwithoursuggestive results indicatesahighpriorprobability
for thepathogenicityofvariants inDYSF (andpossiblyPAXIP1),
and follow-up studies are warranted.
Conclusions
The overall genetic architecture of neurodegenerative dis-
eases is complex and is just beginning to bedefined.Ourwork
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has strengthened the case for 2 AD candidate genes and pro-
videsoneof the firstglimpsesat thisgeneticvariationthathere-
tofore hadnot beenwidely studied.We anticipate that the re-
sults describedhereinwill provide insight into the genetics of
AD,FTD,andPSPandthat thedatawill provideavaluablemul-
tiancestral cohort with exome array genotyping data for fu-
ture studies in each of the 3 diseases.We further expect in the
long term that increased understanding of the genetic under-
pinningswill lead to improvements in diagnosis andmanage-
ment for patients with neurodegenerative diseases.
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